Proportion of trans urethral prostatectomy for benign hyperplasia on total prostatectomy

There are several treatment options for the treatment of benign prostatic hyperplasia: pharmacological treatment, aimed at improving the quality of life by attenuating dysuric symptoms, watchful waiting for patients at low risk of disease progression and surgical treatment, usually a transurethral prostatectomy (TURP). The choice of each of the treatment options requires an assessment of the risks and benefits and this assessment is often entrusted to the doctor, who will have to check whether there are indications for surgery. The ‘Proportion of trans urethral prostatectomy for benign hyperplasia to total prostatectomy’ measures the number of prostatectomies for which there would not appear to be a clear indication for intervention on the total of all prostatectomies performed in a facility. The indicator ‘Hospitalisation for trans-urethral prostatectomy for benign hyperplasia of the prostate’ makes it possible to measure the variability of hospitalisation rates between geographical areas and to identify potential overuse or underuse of the surgical technique, since indications for TURP are unlikely to vary systematically between the areas considered. Further information on: http://95.110.213.190/prevale2014/